Interestingly, in two retrospective studies, it has been demonstrated that TCZ was more clinically beneficial (according to the DAS28 score) than anti-TNF therapy in patients with AA amyloidosis complicating rheumatic diseases (60, 61). This evidence concerns the gene TNF and AA amyloidosis.